Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Anti-inflammatory effects of the GAG-binding CXCL9(74-103) peptide in dinitrofluorobenzene-induced contact hypersensitivity in mice.

Vanheule V, Crijns H, Poosti F, Ruytinx P, Berghmans N, Gerlza T, Ronsse I, Pörtner N, Matthys P, Kungl AJ, Opdenakker G, Struyf S, Proost P.

Clin Exp Allergy. 2018 Oct;48(10):1333-1344. doi: 10.1111/cea.13227. Epub 2018 Aug 14.

PMID:
29978510
2.

Glycosaminoglycans are important mediators of neutrophilic inflammation in vivo.

Gschwandtner M, Strutzmann E, Teixeira MM, Anders HJ, Diedrichs-Möhring M, Gerlza T, Wildner G, Russo RC, Adage T, Kungl AJ.

Cytokine. 2017 Mar;91:65-73. doi: 10.1016/j.cyto.2016.12.008. Epub 2016 Dec 21.

PMID:
28011398
3.

Interfering with the CCL2-glycosaminoglycan axis as a potential approach to modulate neuroinflammation.

Gschwandtner M, Piccinini AM, Gerlza T, Adage T, Kungl AJ.

Neurosci Lett. 2016 Jul 28;626:164-73. doi: 10.1016/j.neulet.2016.05.037. Epub 2016 May 19.

PMID:
27212623
4.

Preparation and Characterization of Glycosaminoglycan Chemokine Coreceptors.

Kitic N, Gschwandtner M, Derler R, Gerlza T, Kungl AJ.

Methods Enzymol. 2016;570:517-38. doi: 10.1016/bs.mie.2015.09.018. Epub 2015 Nov 14.

PMID:
26921960
5.

Designing a mutant CCL2-HSA chimera with high glycosaminoglycan-binding affinity and selectivity.

Gerlza T, Winkler S, Atlic A, Zankl C, Konya V, Kitic N, Strutzmann E, Knebl K, Adage T, Heinemann A, Weis R, Kungl AJ.

Protein Eng Des Sel. 2015 Aug;28(8):231-40. doi: 10.1093/protein/gzv025. Epub 2015 May 11.

PMID:
25969511
6.

Targeting glycosaminoglycans in the lung by an engineered CXCL8 as a novel therapeutic approach to lung inflammation.

Adage T, Konya V, Weber C, Strutzmann E, Fuchs T, Zankl C, Gerlza T, Jeremic D, Heinemann A, Kungl AJ.

Eur J Pharmacol. 2015 Feb 5;748:83-92. doi: 10.1016/j.ejphar.2014.12.019. Epub 2014 Dec 29.

PMID:
25554213
7.

The effect of the decoy molecule PA401 on CXCL8 levels in bronchoalveolar lavage fluid of patients with cystic fibrosis.

McElvaney OJ, O'Reilly N, White M, Lacey N, Pohl K, Gerlza T, Bergin DA, Kerr H, McCarthy C, O'Brien ME, Adage T, Kungl AJ, Reeves EP, McElvaney NG.

Mol Immunol. 2015 Feb;63(2):550-8. doi: 10.1016/j.molimm.2014.10.013. Epub 2014 Nov 2.

PMID:
25453468
8.

A combinatorial approach to biophysically characterise chemokine-glycan binding affinities for drug development.

Gerlza T, Hecher B, Jeremic D, Fuchs T, Gschwandtner M, Falsone A, Gesslbauer B, Kungl AJ.

Molecules. 2014 Jul 22;19(7):10618-34. doi: 10.3390/molecules190710618.

9.

Designing CXCL8-based decoy proteins with strong anti-inflammatory activity in vivo.

Falsone A, Wabitsch V, Geretti E, Potzinger H, Gerlza T, Robinson J, Adage T, Teixeira MM, Kungl AJ.

Biosci Rep. 2013 Sep 17;33(5). pii: e00068. doi: 10.1042/BSR20130069.

10.

Chemokine receptors in gastric MALT lymphoma: loss of CXCR4 and upregulation of CXCR7 is associated with progression to diffuse large B-cell lymphoma.

Deutsch AJ, Steinbauer E, Hofmann NA, Strunk D, Gerlza T, Beham-Schmid C, Schaider H, Neumeister P.

Mod Pathol. 2013 Feb;26(2):182-94. doi: 10.1038/modpathol.2012.134. Epub 2012 Aug 31.

11.

Chlamydia psittaci Infection in nongastrointestinal extranodal MALT lymphomas and their precursor lesions.

Aigelsreiter A, Gerlza T, Deutsch AJ, Leitner E, Beham-Schmid C, Beham A, Popper H, Borel N, Pospischil A, Raderer M, Kessler HH, Neumeister P.

Am J Clin Pathol. 2011 Jan;135(1):70-5. doi: 10.1309/AJCPXMDRT1SY6KIV.

Supplemental Content

Loading ...
Support Center